View Future GrowthMedibank Private 過去の業績過去 基準チェック /36Medibank Privateは、平均年間5.3%の収益成長を遂げていますが、 Insurance業界の収益は、年間 成長しています。収益は、平均年間14.6% 5.3%収益成長率で 成長しています。 Medibank Privateの自己資本利益率は20.2%であり、純利益率は5.3%です。主要情報5.34%収益成長率5.36%EPS成長率Insurance 業界の成長8.02%収益成長率5.25%株主資本利益率20.19%ネット・マージン5.28%次回の業績アップデート19 Aug 2026最近の業績更新お知らせ • May 15Medibank Private Limited to Report Fiscal Year 2026 Results on Aug 20, 2026Medibank Private Limited announced that they will report fiscal year 2026 results at 4:12 PM, AUS Eastern Standard Time on Aug 20, 2026お知らせ • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026お知らせ • Dec 20Medibank Private Limited to Report First Half, 2025 Results on Feb 27, 2025Medibank Private Limited announced that they will report first half, 2025 results on Feb 27, 2025お知らせ • Dec 20Medibank Private Limited to Report First Half, 2024 Results on Feb 22, 2024Medibank Private Limited announced that they will report first half, 2024 results on Feb 22, 2024お知らせ • May 22+ 1 more updateMedibank Private Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Medibank Private Limited announced that they will report fiscal year 2023 results on Aug 24, 2023お知らせ • Dec 16Medibank Private Limited to Report First Half, 2023 Results on Feb 23, 2023Medibank Private Limited announced that they will report first half, 2023 results on Feb 23, 2023すべての更新を表示Recent updatesお知らせ • May 19Medibank Private Limited, Annual General Meeting, Nov 18, 2026Medibank Private Limited, Annual General Meeting, Nov 18, 2026.お知らせ • May 15Medibank Private Limited to Report Fiscal Year 2026 Results on Aug 20, 2026Medibank Private Limited announced that they will report fiscal year 2026 results at 4:12 PM, AUS Eastern Standard Time on Aug 20, 2026お知らせ • Feb 20Medibank Private Limited Declares Fully Franked Interim Ordinary Dividend for the Six Months Ended December 31, 2025 , Payable on March 18, 2026Medibank Private Limited announced the Board has determined a fully franked interim ordinary dividend of AUD 0.08300000 per share for the six months ended December 31, 2025, up 6.4% from the previous year. This dividend represents a 76.8% payout ratio of underlying NPAT, normalising for investment market returns; this is within our annual target payout range of 75%-85% of underlying NPAT. Key dates include: Ex-dividend Date is 26 February 2026; Record Date is 27 February 2026; Payment Date is 18 March 2026.お知らせ • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026お知らせ • Nov 19Medibank Private Limited Approves the Election of Dr. Lisa Mcintyre and Jacqueline Hey as DirectorMedibank Private Limited held its AGM on 19 November 2025, approved the election of Dr. Lisa McIntyre and Jacqueline Hey as a director.お知らせ • Nov 13Jay Weatherill to Retire as Board of Director of Medibank Private Limited, Effective 31 December 2025Medibank Private Limited has announced that non-executive director The Hon Jay Weatherill AO will be retiring from the Medibank Board, effective 31 December 2025, following his recent appointment as the Australian High Commissioner to the United Kingdom. Mr. Weatherill was appointed a director in March 2024 and has served as a member of the Audit Committee and Risk Management Committee.お知らせ • May 16+ 1 more updateMedibank Private Limited, Annual General Meeting, Nov 19, 2025Medibank Private Limited, Annual General Meeting, Nov 19, 2025.お知らせ • Apr 04Medibank Private Limited Announces Consumer Class Action UpdateThe Federal Court has published its decision in the consumer class action on Medibank's claim for legal professional privilege over certain third-party reports and correspondence concerning the 2022 cybercrime event. The Court held that the reports prepared by Deloitte were not subject to legal professional privilege and upheld Medibank's claims to legal professional privilege in respect of the remaining third-party reports and correspondence. Medibank has applied for leave to appeal the decision in relation to the reports by Deloitte.お知らせ • Mar 01Medibank Private Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2024, Payable on March 26, 2025Medibank Private Limited announced ordinary dividend of AUD 0.07800000 per security for the six months ended December 31, 2024. Record Date: March 7, 2025, Ex Date: March 6, 2025 and Payment Date: March 26, 2025.お知らせ • Dec 20Medibank Private Limited to Report First Half, 2025 Results on Feb 27, 2025Medibank Private Limited announced that they will report first half, 2025 results on Feb 27, 2025お知らせ • Sep 13Medibank Private Limited, Annual General Meeting, Nov 13, 2024Medibank Private Limited, Annual General Meeting, Nov 13, 2024. Location: the edge auditorium, federation square, corner swanston street and flinders street, melbourne Australiaお知らせ • Aug 24Medibank Private Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on September 26, 2024Medibank Private Limited announced Ordinary fully franked dividend of AUD 0.09400000 per share for the six months ended June 30, 2024. Ex Date is September 4, 2024. Record Date is September 5, 2024. Payment Date is September 26, 2024.お知らせ • Dec 20Medibank Private Limited to Report First Half, 2024 Results on Feb 22, 2024Medibank Private Limited announced that they will report first half, 2024 results on Feb 22, 2024お知らせ • Oct 05Medibank Private Limited Announces Changes to Executive Leadership TeamMedibank Private Limited announced changes to its executive leadership team. Felicia Trewin will be appointed Group Lead - Data & Technology and Robert Read will be appointed Group Lead - Amplar Health. The latter follows Dr. Andrew Wilson's decision to step back from the executive leadership team and take on the role of Group Chief Medical Officer in a part time capacity. As Group Lead - Data & Technology, Felicia will have a dedicated focus on technology, security, data management and core platforms. Felicia has been Chief Technology Officer at AMP since March 2022. She has more than 25 years of experience in technology including having been the CIO at AustralianSuper, and having previously worked at ANZ, Deloitte, Microsoft and Accenture. Felicia will begin in the role in early 2024 with Kylie Williamson continuing to act in the role until that time. As Group Lead - Amplar Health, Rob will be responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of PHI business and external customers in the private and public sector, including telehealth, in-home care, and healthcare investments. Rob joined Medibank in June 2022 as Amplar Health Chief Commercial Officer. In this role he has been responsible for evolving the health services strategy including focus on virtual health and growing prevention services. Prior to that, Rob was CEO and MD at MedAdvisor Ltd. and has also held senior roles at GSK PLC and as an investor in both venture capital and private equity. Rob will begin in the role on 13 November 2023 with a transition period with Andrew. As Group Chief Medical Officer, Andrew will be responsible for clinical oversight across the business as look to support the triple aim of health: better outcomes, better affordability and better experiences. Andrew has 25 years of experience in the health system and remains a practising clinician and lecturer. Andrew will continue to represent Medibank on a number of investment Boards. Andrew will transition to the role of Group Chief Medical Officer and will carry out the role on a part time basis. Andrew will report to CEO David Koczkar in his new role. As a result of these changes, the executive leadership team will comprise: Chief Executive Officer, David Koczkar Group Lead - People, Spaces & Sustainability, Kylie Bishop Group Lead - Digital & Ventures, Rob Deeming Group Lead - Chief Customer Officer, Milosh Milisavljevic Group Lead - Trust, Legal & Compliance, Group General Counsel and Company Secretary, Mei Ramsay Group Lead - Amplar Health, Robert Read Group Lead - Chief Financial Officer & Group Strategy, Mark Rogers Group Lead - Policy, Advocacy & Reputation, Meaghan Telford Group Lead - Data & Technology, Felicia Trewin.お知らせ • Sep 21Anna Bligh to Retire as Non-Executive Director of Medibank Private Limited At the Conclusion its Annual General Meeting on 22 November 2023Medibank Private Limited announced that non-executive director, Anna Bligh has decided to retire from the Board at the conclusion of the Medibank Annual General Meeting on 22 November 2023. Anna joined the Board in December 2012 and has been a member of the Risk Management Committee,People and Remuneration Committee and the Investment and Capital Committee. Anna joined the Board prior to Medibank's listing on the Australian Securities Exchange ushering the company through the transition from government-owned to privatisation. Anna has brought extensive experience in leadership and public policy, including in healthcare.お知らせ • Aug 24Medibank Private Limited Fully Franked Final Ordinary Dividend for the Six Months Ended 30 June 2023, Payable on 5 October 2023Medibank Private Limited announced that a fully franked final ordinary dividend of 8.30 cents per ordinary share was determined on 24 August 2023 in respect of the six months ended 30 June 2023. This dividend is payable on 5 October 2023 to shareholders on the register at close of business on 14 September 2023. Ex dividend date is September 13, 2023.お知らせ • Jul 28Medibank Private Limited Announces Executive Changes, Effective 31 July 2023Medibank Private Limited announced the executive leadership changes: Group Lead - Chief Financial Officer & Group Strategy - Mark Rogers continues to hold this role with responsibility for finance, actuarial, treasury, internal audit, investor relations, strategy development and M&A. Mark adds procurement to his portfolio of responsibilities. Group Lead - Chief Customer Officer - Milosh Milisavljevic will take on this expanded role. This role brings together the Medibank and ahm brands including marketing, customer channels, customer portfolios, Live Better and diversified insurance. Group Lead - Chief Executive Amplar Health - Dr. Andrew Wilson continues in this role. Andrew is responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of business and government, including telehealth, in-home care, and investments in primary care and ambulatory care. Group Lead - Digital & Ventures - Rob Deeming takes on a new role to accelerate growth in health through the development of digitally-led health products and services for customers and the community. Rob maintains his responsibility for the group digital team supporting insurance and health businesses. Group Lead - Data & Technology - this role will have a dedicated focus on technology, data management and core platforms. An internal and external recruitment process is underway. In the interim Kylie Williamson will continue to act in this role. Group Lead - Trust, Legal & Compliance and Company Secretary - Mei Ramsay will continue to hold this role, with responsibility for customer trust added to her existing portfolio of legal, governance, compliance and regulatory affairs. Mei continues as Company Secretary. Group Lead - People, Spaces & Sustainability - Kylie Bishop will continue to hold this role, with additional responsibility for spaces (property). Kylie continues to lead the key people functions, as well as leading environmental, social and governance focus areas. Group Lead - Policy, Advocacy & Reputation - this is a new role to the executive leadership team. Meaghan Telford will have responsibility for government and industry relations, health stakeholders, health policy, reputation and external communications. Meaghan has been with the company for more than 7 years. These roles report directly to the CEO. The changes are effective 31 July 2023.お知らせ • May 22+ 1 more updateMedibank Private Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Medibank Private Limited announced that they will report fiscal year 2023 results on Aug 24, 2023お知らせ • Feb 07Medibank Announces Class Action Filed in the Federal Court of AustraliaMedibank announced class action against Medibank was filed in the Federal Court of Australia. Medibank understands that these proceedings have been brought on behalf of current and former customers in relation to the cybercrime event Medibank has previously reported and are being brought by Baker & McKenzie and funded by Omni Bridgeway. The statement of claim includes allegations of breach of contract, contraventions of the Australian Consumer Law, and breach of equitable obligations of confidence. Medibank continues to support its customers from the impact of the cybercrime through our previously announced Cyber Response Support Program which includes mental health and wellbeing support, identity protection and financial hardship measures.お知らせ • Dec 16Medibank Private Limited to Report First Half, 2023 Results on Feb 23, 2023Medibank Private Limited announced that they will report first half, 2023 results on Feb 23, 2023収支内訳Medibank Private の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:MDBP.F 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 258,770463674030 Sep 258,663482666030 Jun 258,556501657031 Mar 258,446495642031 Dec 248,335490628030 Sep 248,182491624030 Jun 248,030493620031 Mar 247,939488610031 Dec 237,848483601030 Sep 237,623396584030 Jun 237,398309567031 Mar 237,261326620031 Dec 227,124343674030 Sep 227,114368713030 Jun 227,105394752031 Mar 227,117414738031 Dec 217,130435725030 Sep 217,081438720030 Jun 217,032441716031 Mar 216,930402720031 Dec 206,829363725030 Sep 206,804340718030 Jun 206,779316712031 Mar 206,836368707031 Dec 196,892420701030 Sep 196,829429711030 Jun 196,765438721031 Dec 186,381375501030 Sep 186,479400594030 Jun 186,577424686031 Mar 187,0104541,082031 Dec 177,0064631,070030 Sep 176,9774561,072030 Jun 176,9484501,073031 Mar 176,9144361,060031 Dec 166,8794221,047030 Sep 166,8434201,051030 Jun 166,8074181,055031 Mar 166,7913931,075031 Dec 156,7743691,095030 Sep 156,7283271,102030 Jun 156,6822851,1090質の高い収益: MDBP.Fは 高品質の収益 を持っています。利益率の向上: MDBP.Fの現在の純利益率 (5.3%)は、昨年(5.9%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MDBP.Fの収益は過去 5 年間で年間5.3%増加しました。成長の加速: MDBP.Fは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: MDBP.Fは過去 1 年間で収益成長率がマイナス ( -5.4% ) となったため、 Insurance業界平均 ( 36.2% ) と比較することが困難です。株主資本利益率高いROE: MDBP.Fの 自己資本利益率 ( 20.2% ) は 高い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YInsurance 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 08:08終値2026/05/13 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medibank Private Limited 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20 アナリスト機関Andrew AdamsBarrenjoey Markets Pty LimitedJohn HesterBell PotterFreya KongBofA Global Research17 その他のアナリストを表示
お知らせ • May 15Medibank Private Limited to Report Fiscal Year 2026 Results on Aug 20, 2026Medibank Private Limited announced that they will report fiscal year 2026 results at 4:12 PM, AUS Eastern Standard Time on Aug 20, 2026
お知らせ • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026
お知らせ • Dec 20Medibank Private Limited to Report First Half, 2025 Results on Feb 27, 2025Medibank Private Limited announced that they will report first half, 2025 results on Feb 27, 2025
お知らせ • Dec 20Medibank Private Limited to Report First Half, 2024 Results on Feb 22, 2024Medibank Private Limited announced that they will report first half, 2024 results on Feb 22, 2024
お知らせ • May 22+ 1 more updateMedibank Private Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Medibank Private Limited announced that they will report fiscal year 2023 results on Aug 24, 2023
お知らせ • Dec 16Medibank Private Limited to Report First Half, 2023 Results on Feb 23, 2023Medibank Private Limited announced that they will report first half, 2023 results on Feb 23, 2023
お知らせ • May 19Medibank Private Limited, Annual General Meeting, Nov 18, 2026Medibank Private Limited, Annual General Meeting, Nov 18, 2026.
お知らせ • May 15Medibank Private Limited to Report Fiscal Year 2026 Results on Aug 20, 2026Medibank Private Limited announced that they will report fiscal year 2026 results at 4:12 PM, AUS Eastern Standard Time on Aug 20, 2026
お知らせ • Feb 20Medibank Private Limited Declares Fully Franked Interim Ordinary Dividend for the Six Months Ended December 31, 2025 , Payable on March 18, 2026Medibank Private Limited announced the Board has determined a fully franked interim ordinary dividend of AUD 0.08300000 per share for the six months ended December 31, 2025, up 6.4% from the previous year. This dividend represents a 76.8% payout ratio of underlying NPAT, normalising for investment market returns; this is within our annual target payout range of 75%-85% of underlying NPAT. Key dates include: Ex-dividend Date is 26 February 2026; Record Date is 27 February 2026; Payment Date is 18 March 2026.
お知らせ • Dec 12Medibank Private Limited to Report First Half, 2026 Results on Feb 19, 2026Medibank Private Limited announced that they will report first half, 2026 results on Feb 19, 2026
お知らせ • Nov 19Medibank Private Limited Approves the Election of Dr. Lisa Mcintyre and Jacqueline Hey as DirectorMedibank Private Limited held its AGM on 19 November 2025, approved the election of Dr. Lisa McIntyre and Jacqueline Hey as a director.
お知らせ • Nov 13Jay Weatherill to Retire as Board of Director of Medibank Private Limited, Effective 31 December 2025Medibank Private Limited has announced that non-executive director The Hon Jay Weatherill AO will be retiring from the Medibank Board, effective 31 December 2025, following his recent appointment as the Australian High Commissioner to the United Kingdom. Mr. Weatherill was appointed a director in March 2024 and has served as a member of the Audit Committee and Risk Management Committee.
お知らせ • May 16+ 1 more updateMedibank Private Limited, Annual General Meeting, Nov 19, 2025Medibank Private Limited, Annual General Meeting, Nov 19, 2025.
お知らせ • Apr 04Medibank Private Limited Announces Consumer Class Action UpdateThe Federal Court has published its decision in the consumer class action on Medibank's claim for legal professional privilege over certain third-party reports and correspondence concerning the 2022 cybercrime event. The Court held that the reports prepared by Deloitte were not subject to legal professional privilege and upheld Medibank's claims to legal professional privilege in respect of the remaining third-party reports and correspondence. Medibank has applied for leave to appeal the decision in relation to the reports by Deloitte.
お知らせ • Mar 01Medibank Private Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2024, Payable on March 26, 2025Medibank Private Limited announced ordinary dividend of AUD 0.07800000 per security for the six months ended December 31, 2024. Record Date: March 7, 2025, Ex Date: March 6, 2025 and Payment Date: March 26, 2025.
お知らせ • Dec 20Medibank Private Limited to Report First Half, 2025 Results on Feb 27, 2025Medibank Private Limited announced that they will report first half, 2025 results on Feb 27, 2025
お知らせ • Sep 13Medibank Private Limited, Annual General Meeting, Nov 13, 2024Medibank Private Limited, Annual General Meeting, Nov 13, 2024. Location: the edge auditorium, federation square, corner swanston street and flinders street, melbourne Australia
お知らせ • Aug 24Medibank Private Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on September 26, 2024Medibank Private Limited announced Ordinary fully franked dividend of AUD 0.09400000 per share for the six months ended June 30, 2024. Ex Date is September 4, 2024. Record Date is September 5, 2024. Payment Date is September 26, 2024.
お知らせ • Dec 20Medibank Private Limited to Report First Half, 2024 Results on Feb 22, 2024Medibank Private Limited announced that they will report first half, 2024 results on Feb 22, 2024
お知らせ • Oct 05Medibank Private Limited Announces Changes to Executive Leadership TeamMedibank Private Limited announced changes to its executive leadership team. Felicia Trewin will be appointed Group Lead - Data & Technology and Robert Read will be appointed Group Lead - Amplar Health. The latter follows Dr. Andrew Wilson's decision to step back from the executive leadership team and take on the role of Group Chief Medical Officer in a part time capacity. As Group Lead - Data & Technology, Felicia will have a dedicated focus on technology, security, data management and core platforms. Felicia has been Chief Technology Officer at AMP since March 2022. She has more than 25 years of experience in technology including having been the CIO at AustralianSuper, and having previously worked at ANZ, Deloitte, Microsoft and Accenture. Felicia will begin in the role in early 2024 with Kylie Williamson continuing to act in the role until that time. As Group Lead - Amplar Health, Rob will be responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of PHI business and external customers in the private and public sector, including telehealth, in-home care, and healthcare investments. Rob joined Medibank in June 2022 as Amplar Health Chief Commercial Officer. In this role he has been responsible for evolving the health services strategy including focus on virtual health and growing prevention services. Prior to that, Rob was CEO and MD at MedAdvisor Ltd. and has also held senior roles at GSK PLC and as an investor in both venture capital and private equity. Rob will begin in the role on 13 November 2023 with a transition period with Andrew. As Group Chief Medical Officer, Andrew will be responsible for clinical oversight across the business as look to support the triple aim of health: better outcomes, better affordability and better experiences. Andrew has 25 years of experience in the health system and remains a practising clinician and lecturer. Andrew will continue to represent Medibank on a number of investment Boards. Andrew will transition to the role of Group Chief Medical Officer and will carry out the role on a part time basis. Andrew will report to CEO David Koczkar in his new role. As a result of these changes, the executive leadership team will comprise: Chief Executive Officer, David Koczkar Group Lead - People, Spaces & Sustainability, Kylie Bishop Group Lead - Digital & Ventures, Rob Deeming Group Lead - Chief Customer Officer, Milosh Milisavljevic Group Lead - Trust, Legal & Compliance, Group General Counsel and Company Secretary, Mei Ramsay Group Lead - Amplar Health, Robert Read Group Lead - Chief Financial Officer & Group Strategy, Mark Rogers Group Lead - Policy, Advocacy & Reputation, Meaghan Telford Group Lead - Data & Technology, Felicia Trewin.
お知らせ • Sep 21Anna Bligh to Retire as Non-Executive Director of Medibank Private Limited At the Conclusion its Annual General Meeting on 22 November 2023Medibank Private Limited announced that non-executive director, Anna Bligh has decided to retire from the Board at the conclusion of the Medibank Annual General Meeting on 22 November 2023. Anna joined the Board in December 2012 and has been a member of the Risk Management Committee,People and Remuneration Committee and the Investment and Capital Committee. Anna joined the Board prior to Medibank's listing on the Australian Securities Exchange ushering the company through the transition from government-owned to privatisation. Anna has brought extensive experience in leadership and public policy, including in healthcare.
お知らせ • Aug 24Medibank Private Limited Fully Franked Final Ordinary Dividend for the Six Months Ended 30 June 2023, Payable on 5 October 2023Medibank Private Limited announced that a fully franked final ordinary dividend of 8.30 cents per ordinary share was determined on 24 August 2023 in respect of the six months ended 30 June 2023. This dividend is payable on 5 October 2023 to shareholders on the register at close of business on 14 September 2023. Ex dividend date is September 13, 2023.
お知らせ • Jul 28Medibank Private Limited Announces Executive Changes, Effective 31 July 2023Medibank Private Limited announced the executive leadership changes: Group Lead - Chief Financial Officer & Group Strategy - Mark Rogers continues to hold this role with responsibility for finance, actuarial, treasury, internal audit, investor relations, strategy development and M&A. Mark adds procurement to his portfolio of responsibilities. Group Lead - Chief Customer Officer - Milosh Milisavljevic will take on this expanded role. This role brings together the Medibank and ahm brands including marketing, customer channels, customer portfolios, Live Better and diversified insurance. Group Lead - Chief Executive Amplar Health - Dr. Andrew Wilson continues in this role. Andrew is responsible for Medibank's growing role as a health services provider. This includes responsibility for the health services deliver on behalf of business and government, including telehealth, in-home care, and investments in primary care and ambulatory care. Group Lead - Digital & Ventures - Rob Deeming takes on a new role to accelerate growth in health through the development of digitally-led health products and services for customers and the community. Rob maintains his responsibility for the group digital team supporting insurance and health businesses. Group Lead - Data & Technology - this role will have a dedicated focus on technology, data management and core platforms. An internal and external recruitment process is underway. In the interim Kylie Williamson will continue to act in this role. Group Lead - Trust, Legal & Compliance and Company Secretary - Mei Ramsay will continue to hold this role, with responsibility for customer trust added to her existing portfolio of legal, governance, compliance and regulatory affairs. Mei continues as Company Secretary. Group Lead - People, Spaces & Sustainability - Kylie Bishop will continue to hold this role, with additional responsibility for spaces (property). Kylie continues to lead the key people functions, as well as leading environmental, social and governance focus areas. Group Lead - Policy, Advocacy & Reputation - this is a new role to the executive leadership team. Meaghan Telford will have responsibility for government and industry relations, health stakeholders, health policy, reputation and external communications. Meaghan has been with the company for more than 7 years. These roles report directly to the CEO. The changes are effective 31 July 2023.
お知らせ • May 22+ 1 more updateMedibank Private Limited to Report Fiscal Year 2023 Results on Aug 24, 2023Medibank Private Limited announced that they will report fiscal year 2023 results on Aug 24, 2023
お知らせ • Feb 07Medibank Announces Class Action Filed in the Federal Court of AustraliaMedibank announced class action against Medibank was filed in the Federal Court of Australia. Medibank understands that these proceedings have been brought on behalf of current and former customers in relation to the cybercrime event Medibank has previously reported and are being brought by Baker & McKenzie and funded by Omni Bridgeway. The statement of claim includes allegations of breach of contract, contraventions of the Australian Consumer Law, and breach of equitable obligations of confidence. Medibank continues to support its customers from the impact of the cybercrime through our previously announced Cyber Response Support Program which includes mental health and wellbeing support, identity protection and financial hardship measures.
お知らせ • Dec 16Medibank Private Limited to Report First Half, 2023 Results on Feb 23, 2023Medibank Private Limited announced that they will report first half, 2023 results on Feb 23, 2023